Radiopharm Theranostics Ltd has released a press release.
FDA grants Orphan drug status to RAD DUNP19 for Osteosarcoma
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- RAD Licenses UCLA Dual Action Antibody
- LOI with GenesisCare to start first trial in Australia
- Radiopharm and TerraPower sign Actinium 225 agreement
- RAD acquires IP Ownership of Radiopharmaceutical Nanobodies
- RAD Integrins technology featured in Cancers journal
Later from Radiopharm Theranostics
- FDA grants rare pediatric disease designation for DUNP19
- Suspension from Official Quotation
- Presentation - Pivalate achieves positive Phase 2 data
- Pivalate achieves positive Phase 2 data in brain mets trial
- Entitlement Offer to raise up to $10 million
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics